Company: INDP
Filing Date: 2025-09-02
Form Type: 424B5
Source: 0001493152-25-012530
Chunk: 0

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-09-02
Form: 424B5
Chunk 0
---
As Filed Pursuant to Rule 424(b)(5)

Registration No. 333-289573

PROSPECTUS SUPPLEMENT

(To Prospectus dated August 20, 2025)

<div align='center'>INDAPTUS THERAPEUTICS, INC.

Up to $2,340,000

Shares of Common Stock</div>

We have entered into an at-the-market offering agreement, or the Offering Agreement, dated June 1, 2022, as amended, with H.C. Wainwright & Co., LLC, or the Sales Agent or Wainwright, as sales agent relating to the shares of our common stock, par value $0.01 per share, offered by this prospectus supplement and accompanying prospectus. As of September 1, 2025, we have sold 5,428 shares of our common stock under the Offering Agreement for aggregate gross proceeds of approximately $0.4 million pursuant to a prior prospectus relating to Form S-3 (333-267236) filed with the Securities and Exchange Commission on September 1, 2022. Pursuant to this prospectus supplement, we may offer and sell shares of our common stock having an aggregate offering price of up to $2,340,000.

Sales of our common stock, if any, under this prospectus supplement and the accompanying prospectus may be made in transactions that are deemed to be “at-the-market” offerings as defined in Rule 415 under the Securities Act of 1933, as amended, or the Securities Act, including sales made directly on or through The Nasdaq Capital Market, or Nasdaq, the existing trading market for our common stock, or any other existing trading market in the Unites States for our shares of common stock, sales made to or through a market maker other than on an exchange or otherwise, directly to the Sales Agent as principal, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, and/or in any other method permitted by law. If we and Wainwright agree on any method of distribution other than sales of our common stock into Nasdaq or another existing trading market in the United States at market prices, we will file an additional prospectus supplement providing all information about such offering as required by Rule 424(b) under the Securities Act. Wainwright is not required to sell any specific amount, but will act as our sales agent using commercially reasonable efforts consistent with its normal trading and sales practices. There is